Member Info for Krone

There are four key messages: 1) we are an experienced JAK inhibitor development team with exceptional insight into momelotinib; 2) critically, momelotinib uniquely addresses anemia in myelofibrosis, while also providing meaningful benefits on spleen and symptoms; 3) a robust body of existing clinical data are at hand to help guide, support and validate our proposed registration strategy; and 4) momelotinib has broad development opportunities beyond MF.

And what Stephen Parker up to? No tangible evidence of any added value whatsoever!

Presentation being reflected in Sierra SP?

If this comes to fruition I am sure you will get *****d any way you like!

Sierra presentation tomorrow - are we expecting anything significant?

Will they dose before recruitment ends or will they wait until the trial is fully recruited?

Presumably they won't wait until recruitment is fully completed before dosing commences given the likelihood of disease progression in the selected recruits and the ethical/clinical issues this would raise.

Will they dose before recruitment ends or will they wait until the trial is fully recruited?

Presumably they won't wait until recruitment is fully completed before dosing commences given the likelihood of disease progression in the selected recruits and the ethical/clinical issues this would raise.

Given the significant delays in the SRI Tyk2 update, removal of the paper from Sar's website etc etc what is the liklihood of a combined announcement on candidate selection and licencing agreement/s?

Thanks Thoth, would you expect NG to refer to this on 15th and if not why not?

May provide further details on current position.

Potentially significant positive impact on milestone payment.....

Thanks Thoth, holding tight and hoping for the best...soon!!!

Thanks Ahfam, are WH Ireland the best nomad in the business? Their website looks a tad amateur.

The seemingly endless stream of potential applications for Tyk2 must make the negotiation of any licencing deal hellishly complicated with massive scope for underselling ourselves....do we have a sufficiently skilled and experienced team to realise the full value in all our targets!

https://endpts.com/agios-scores-its-second-new-drug-approval-ivosidenib-heads-to-the-aml-market/

Interesting context re FDA approval of fast track AML treatment based on early stage 1 data... Billed as “the first targeted treatment for R/R AML patients with an IDH1 mutation,” Agios submitted it back in February with nothing but early-stage data that had been on display at ASH.

Recent LinkedIn post from Nick Glover...SRA737 + LDG being tested in a cohort of soft tissue sarcoma patients in Sierra's ongoing P1/2 study (NCT02797977); significant unmet medical need for new treatments for this heterogeneous group of cancers. Presumably he wouldn’t be posting if the emerging data weren’t promising.

Yes, Sierra have been tweeting about Sarcoma for a few weeks...

Subsequent to the December2017 AGM, John Reader indicated that a response from the US patent office in respect of US Tyk2 appeal is expected within +-12 months. Given that the application was submitted in September 2017 we should hear something in less that 3 months...along with all the other updates which are stacking up....

...or is the storm on the way?